COVID-19

How much progress have we made in developing therapies to treat this common childhood respiratory disorder?

Following some improvement, excess death rate returned to 1999 levels for Black men and 2005 levels for Black women.

Unvaccinated patients who were older at MG onset and at SARS-CoV-2 infection had more severe cases.

While acknowledging remaining uncertainties posed by potential evolution of SARS-CoV-2, the organization advised it’s time to transition to long-term management of the pandemic.

Though the Omicron variant caused the most symptoms in pediatric patients, there were no differences in adverse outcomes by COVID-19 variant.

According to a recent study, pregnant women infected with COVID-19 experienced significant maternal mortality during pregnancy, with worse outcomes during the second wave of the pandemic compared to the first.

Monovalent vaccines by these manufacturers are no longer authorized for use in the United States.

Despite a massive COVID-19 vaccination campaign, many still fear a return to normal.

Project NextGen will focus on the development of vaccines and long-lasting monoclonal antibody COVID-19 treatments.

Researchers of a new study investigated what's causing vaccine hesitancy, and why individuals are feeling vaccine fatigue.

The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.

From variants to vaccines, much has changed in the COVID-19 landscape.

The supplemental biologics license application seeks approval for the Omicron BA.4/BA.5 bivalent vaccine as both a primary series and a booster dose.

More traditional health care coverage will begin when the U.S. public health emergency response to COVID-19 ends on May 11.

The vaccine was 73.2% effective in children aged 6 months to 4 years when administered during the Omicron-dominant phase.

Researchers estimate the protection from COVID-19 reinfection based on the variant and time since a patient's previous infection.

Federal regulators need to address potential policy changes that could affect primary care.

Viruses are known to precipitate autoimmune diseases, but the link between COVID-19 and autoimmune conditions requires additional research.

The updated vaccine schedule includes vaccinations for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

XBB, a less severe but more contagious strain of COVID-19, has taken over as the dominant Omicron strain.

A 2021 morbidity study found that COVID-19 was among the leading causes of death in children and young people.

Vaccination greatly reduces the probability of experiencing severe COVID-19 in both variants. Adults between the ages of 40 to 59 years saw the most significant reduction in risk when compared to individuals in other age categories.

“Vaccination coverage among pregnant women remains a priority,” the researchers wrote.

The public health emergency, which was set to end April 11, and the national emergency, which was set to end March 1, will be ended on May 11 by the Biden administration.

Pfizer Inc. and Moderna Inc. have indicated that they are going to price their shots at between $110 and $130. The shots should still be free to individuals because of rules barring out-of-pocket costs for such vaccinations.